Literature DB >> 12513927

Adjuvant danger signals increase the immune response to porcine reproductive and respiratory syndrome virus.

Dennis L Foss1, Michael J Zilliox, William Meier, Federico Zuckermann, Michael P Murtaugh.   

Abstract

The immune response of swine to vaccination with a live, attenuated PRRSV was assessed in the presence and absence of cytokine adjuvants or cholera toxin (CT) to address the hypothesis that adjuvant danger signals, that is, inflammatory cytokines and bacterial extoxin, stimulate a more robust immune response. Animals received four injections of recombinant porcine IL-1 and IL-6, IL-12 alone, or CT alone within 1 week of intramuscular administration of a vaccine strain of PRRSV, Ingelvac MLV. Serological and cell-mediated responses were monitored for 42 days after vaccination and for a further 10 days after challenge with the virulent VR2332 strain of PRRSV. First, the principal observation was an enhancing effect of IL-12 on the interferon gamma response to PRRSV, with a more rapid and heightened PRRSV-specific interferon gamma ELISPOT response in peripheral blood mononuclear cells. The more rapid and robust development of a cell-mediated immune response, as determined by this assay, suggests that IL-12 may influence the induction of antigen-specific T cell responses. Second, animals that received CT adjuvant displayed a more robust antibody response to GP5, the major envelope glycoprotein. Anti-GP5 titers peaked at 21 days after vaccination at more than twice the level of any other treatment, for which the peak response was at 28 days. Third, there was no evidence of PRRSV immunosuppression of immunity to unrelated antigens, including circovirus. CT is a potent mucosal adjuvant, particularly for antibody responses. It acts in part through the production of IL-1 in macrophages, but its effect was not replaced by combination treatment with IL-1 and IL-6. In sum, the results suggest that cytokine adjuvants, particularly IL-12, and CT have the potential to enhance immune responses to live viral vaccines.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12513927     DOI: 10.1089/088282402320914502

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  21 in total

1.  Reproductive parameters following a PRRS outbreak where a whole-herd PRRS MLV vaccination strategy was instituted post-outbreak.

Authors:  Em-on Olanratmanee; Suparlark Nuntawan Na Ayudhya; Roongroje Thanawongnuwech; Annop Kunavongkrit; Padet Tummaruk
Journal:  Trop Anim Health Prod       Date:  2012-12-02       Impact factor: 1.559

Review 2.  Advances in swine immunology help move vaccine technology forward.

Authors:  Michael P Murtaugh
Journal:  Vet Immunol Immunopathol       Date:  2014-02-23       Impact factor: 2.046

3.  Immunopotentiation of four natural adjuvants co-administered with a highly pathogenic porcine reproductive and respiratory syndrome virus glycoprotein 5 subunit.

Authors:  Jun Peng; Yanmei Yuan; Si Shen; Zhongxiang Niu; Yijun Du; Jiaqiang Wu; Jun Li; Jiang Yu; Tao Wang; Jinbao Wang
Journal:  Virus Genes       Date:  2016-02-08       Impact factor: 2.332

4.  Assessment of the safety and efficacy of an attenuated live vaccine based on highly pathogenic porcine reproductive and respiratory syndrome virus.

Authors:  Xiuling Yu; Zhi Zhou; Zhen Cao; Jiajun Wu; Zhongqiu Zhang; Baiwan Xu; Chuanbin Wang; Dongmei Hu; Xiaoyu Deng; Wei Han; Xiaoxue Gu; Shuo Zhang; Xiaoxia Li; Baoyue Wang; Xinyan Zhai; Kegong Tian
Journal:  Clin Vaccine Immunol       Date:  2015-03-04

5.  Phylogeny-based evolutionary, demographical, and geographical dissection of North American type 2 porcine reproductive and respiratory syndrome viruses.

Authors:  Mang Shi; Tommy Tsan-Yuk Lam; Chung-Chau Hon; Michael P Murtaugh; Peter R Davies; Raymond Kin-Hei Hui; Jun Li; Lina Tik-Wim Wong; Chi-Wai Yip; Jin-Wai Jiang; Frederick Chi-Ching Leung
Journal:  J Virol       Date:  2010-06-16       Impact factor: 5.103

6.  The level of virus-specific T-cell and macrophage recruitment in porcine reproductive and respiratory syndrome virus infection in pigs is independent of virus load.

Authors:  Zhengguo Xiao; Laura Batista; Scott Dee; Patrick Halbur; Michael P Murtaugh
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

7.  Antigen-specific B-cell responses to porcine reproductive and respiratory syndrome virus infection.

Authors:  Prasad Mulupuri; Jeffrey J Zimmerman; Joseph Hermann; Craig R Johnson; Jean Paul Cano; Wanqin Yu; Scott A Dee; Michael P Murtaugh
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

8.  Evaluation of immune responses to porcine reproductive and respiratory syndrome virus in pigs during early stage of infection under farm conditions.

Authors:  Varun Dwivedi; Cordelia Manickam; Basavaraj Binjawadagi; Daniel Linhares; Michael P Murtaugh; Gourapura J Renukaradhya
Journal:  Virol J       Date:  2012-02-16       Impact factor: 4.099

9.  Construction and in vitro evaluation of a recombinant live attenuated PRRSV expressing GM-CSF.

Authors:  Lingxue Yu; Yanjun Zhou; Yifeng Jiang; Wu Tong; Shen Yang; Fei Gao; Kang Wang; Liwei Li; Tianqi Xia; Qun Cheng; Guangzhi Tong
Journal:  Virol J       Date:  2014-11-25       Impact factor: 4.099

10.  Evaluation of Different DNA Vaccines against Porcine Reproductive and Respiratory Syndrome (PRRS) in Pigs.

Authors:  Stefano Petrini; Giorgio Ramadori; Riccardo Villa; Paolo Borghetti; Elena de Angelis; Anna Maria Cantoni; Attilio Corradi; Augusto Amici; Maura Ferrari
Journal:  Vaccines (Basel)       Date:  2013-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.